Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Posts First Ever Net Loss Due To Heavy Investment

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Eisai posted losses in net income for fiscal 2007 due to heavy investment in oncology research and development through recent acquisitions. Eisai's losses were a first since it became a listed company in 1961

You may also be interested in...



Eisai’s Aciphex Cleared In U.S. For Adolescent GERD, Matching Broader Label Of Other PPIs

Already cleared for gastroesophageal reflux disease in adults, Eisai's Aciphex won U.S. FDA clearance June 30 for short-term use by adolescents age 12 and higher

Eisai’s Aciphex Cleared In U.S. For Adolescent GERD, Matching Broader Label Of Other PPIs

Already cleared for gastroesophageal reflux disease in adults, Eisai's Aciphex won U.S. FDA clearance June 30 for short-term use by adolescents age 12 and higher

MHLW Approves Abbott’s Humira To Be Distributed By Eisai In Japan

TOKYO - In contrast to wide criticisms about long drug lags in Japan, the Ministry of Health, Labor and Welfare has approved Abbott's rheumatoid arthritis antibody drug Humira (adalimumab) to be distributed by Eisai in Japan, the two companies announced June 17

Related Content

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel